We're on a mission to transform cancer care.
Unlocking precision oncology through human biology.
Founded in 2018 as a spin-out from the Weizmann Institute of Science, CURESPONSE was built on a single conviction: the most accurate predictor of how a patient will respond to cancer treatment is the patient's own tumor tissue. The company operates through three regional labs, in Israel, the UK, and the US.
Human first
Every answer comes from living human tumor tissue. No proxies, no shortcuts, no surrogates.
Clinically validated
90%+ PPV and NPV. Every claim is backed by published data and independent institutional validation.
Rigorous quality
CE marked. ISO 15189:2022 Medical Laboratories. Regulatory-grade standards applied to every sample and report.
Patient impact
De-escalation and intensification guidance that directly reduces toxicity, costs, and futile treatment.
Scientific partnership
Adaptive, collaborative projects with clinicians, pharma teams, and payers, built around real questions.
AI-augmented
AI across every layer of our platform, from indication navigation to biomarker discovery and pipeline audit.
"Every cancer patient deserves a treatment decision grounded in the biology of their own tumor, not population averages, not animal models, not guesswork."
Zvika Slovin
Experienced biotech/medtech leader and investor with multiple exec and non-exec roles. Founded, managed and successfully exited numerous medtech companies.
Yanki Galanti
Vast experience in medical and high-tech investments. Previously GP and managing director of GEOC investment fund, focused on life sciences and medical device companies.
Prof. Ravid Straussman, MD PhD
Associate professor at the Weizmann Institute of Science. Leads a cancer research group in the Department of Molecular Cell Biology.
Vered Bar, PhD
Vast experience managing R&D projects within the pharmaceutical industry. Previously Chief Scientific Advisor of Forum-MD.
Ronen Viner
Vast experience in strategy and business development in pharma and healthcare. Previously Head of Strategy, Innovation and Business Development at Meuhedet HMO.
Guy Neev
Over 20 years experience in medical and high-tech industries. Previously CEO of Nasdaq-listed Check-Cap Ltd and ArraVasc.
Seth Salpeter, PhD
Previously Chief Scientist and VP BD at Sight Diagnostics. Pharmaceutical Analyst at Biotechnology General (Ferring).
Eran Dor
Founder, Real Numbers Ltd. Previously Head of Finance and Operation at TrapX Security. Previously CFO at Monterey Bay Labs.
Omer Goldman
Ph.D.-trained biologist from the Weizmann Institute with hands-on expertise in oncology and immunometabolism. Previously executed in-vitro and in-vivo oncology R&D at ReadeRx Therapeutics.
Sandra Hanks, PhD
Extensive experience in laboratory management. Clinical Genomics Laboratory Manager at The Royal Marsden NHS Foundation Trust.
Prof. Ravid Straussman, MD PhD
Associate Professor, Department of Molecular Cell Biology, Weizmann Institute of Science.
Prof. Raanan Berger, MD PhD
Head, Institute of Oncology, Sheba Medical Center, Tel Aviv. Member of ESMO and ASCO.
Prof. Talia Golan, MD
Head, Pancreatic Cancer Center, Sheba Medical Center. 297+ publications.
Prof. Toni K. Choueiri, MD
Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute. Harvard Medical School. 800+ publications.
Base44 Founder Maor Shlomo Backs CURESPONSE Through New Cancer Research Fund
Maor Shlomo, founder of Base44 (sold to Wix for $80M), called on his network for recommendations on promising cancer research companies to invest in. He revealed CURESPONSE as one of seven companies he backed through a new private fund, citing its functional testing on real cancer biopsies to show drug efficacy with high precision.
USPTO Allows U.S. Patent Claims for cResponse™-Discovered MEK-Src Combination Therapy in Colorectal Cancer
The USPTO issued a Notice of Allowance covering the MEK-Src combination therapy discovered via the cResponse™ platform, extending CURESPONSE's earlier European patent into the U.S. market. The claims cover a biomarker-defined patient subgroup shown to respond at a substantially higher rate than an unselected population.
CURESPONSE & Jefferson Health Launch IIA-Funded Interventional Study, Entering the U.S. Market
CURESPONSE secured an Israel Innovation Authority grant and entered a collaboration with Jefferson Health (Sidney Kimmel Medical College, Philadelphia), marking formal entry into the U.S. market. The partnership includes a randomized controlled trial across 200+ patients in metastatic breast, pancreatic, and sarcoma indications.
Peer-Reviewed Study Confirms Clinical Utility of cResponse™ in Real-World Oncology Practice
A post-market surveillance study of 312 patients found cResponse™ achieved 96.9% sensitivity, 76.9% specificity, 91.2% PPV, and 90.9% NPV against real-world clinical outcomes, influencing physician treatment decisions in 51.1% of correlated cases.
CURESPONSE Selected for ScaIL UK Programme
A selective programme supporting the expansion of promising Israeli scaleups into the UK market, connecting companies with strategic partners and growth opportunities across the UK ecosystem.
CURESPONSE Awarded European Patent for Novel MEK-Src Combination Therapy in Colorectal Cancer
CURESPONSE was awarded a European patent for a novel MEK-Src combination therapy in colorectal cancer, validated on live human tumors using the cResponse™ platform.
CURESPONSE Joins Israel’s Health-Tech U.S. Roadshow
CURESPONSE joined Israel's Health-Tech Roadshow to the United States, showcasing the cResponse™ precision oncology platform to healthcare institutions, investors, and pharma partners.
CURESPONSE Presents Functional Oncology Platform at Tumour Models London Summit 2024
Dr. Vered Bar, VP R&D, presented the cResponse™ ex-vivo functional platform to pharma and biotech leaders, highlighting applications across biologics, immuno-oncology, ADCs, and CAR-T pipeline development.
Selected for Israel's Innovation Dream Team 2024/2025
CURESPONSE was selected by a special committee from hundreds of nominee companies to be featured as part of the Israeli Innovation Dream Team for 2024/2025.
EDX Medical Group to Exclusively Distribute cResponse™ in the UK, Sweden, Finland, Norway & Denmark
CURESPONSE signed an exclusive distribution agreement with EDX Medical Group plc to market cResponse™ across the UK and Nordic region for chemotherapy, targeted biologics, and immunotherapy decisions.
cResponse™ Data Featured in Study on Platinum & PARP Inhibitor Response in BRCA-Associated Pancreatic Cancer
A study led by Dr. Talia Golan and Dr. Chani Stossel at Sheba Medical Center's Oncology Institute used cResponse™ to correlate ex-vivo drug sensitivity with clinical outcomes in germline BRCA-associated pancreatic cancer.
Positive Preliminary Results from Multi-Center UK Study Presented at AACR
Combined UK and Israel clinical data demonstrated 96.5% sensitivity and 90% specificity across multiple solid cancer types, presented at the AACR annual meeting by Principal Investigator Dr. Jon Krell of Imperial College London.
Clalit Health Services to Provide Commercial Coverage for cResponse™
Clalit Health Services, the world's second-largest HMO, included cResponse™ in its Oncology Services package, significantly expanding patient access to functional precision oncology testing.
cResponse™ Shows Applicability of Next-Generation IO Drugs at SITC
CURESPONSE presented results demonstrating applicability of next-generation immuno-oncology compounds in the pan-cancer cResponse™ system at the SITC annual meeting, Europe's largest IO-focused conference.
Rafael Advanced Defense Systems and CURESPONSE to Collaborate on AI for Precision Oncology
CURESPONSE and Rafael Advanced Defense Systems announced a strategic collaboration to integrate Rafael's AI capabilities into the cResponse™ drug sensitivity platform.
CURESPONSE Secures $6M Series A for Precision Oncology Expansion
CURESPONSE raised $6M in Series A funding from NCL Technology Ventures (UK) and aMoon (Israel) to scale clinical validation programs and expand internationally to the UK.
Ordering a test, asking your doctor about cResponse™, requesting a policy discussion, or starting a pharma project each have their own dedicated path, see the For Clinicians, For Patients, For Payers, and For Pharma pages.